BiotechTube

Pegloticase

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Uncontrolled Gout

Conditions

Uncontrolled Gout, Kidney Transplant

Trial Timeline

Sep 9, 2019 → Sep 7, 2021

NCT ID
NCT04087720

About Pegloticase

Pegloticase is a approved stage product being developed by Amgen for Uncontrolled Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT04087720. Target conditions include Uncontrolled Gout, Kidney Transplant.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04087720ApprovedCompleted

Competing Products

17 competing products in Uncontrolled Gout

See all competitors
ProductCompanyStageHype Score
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
77
Baxdrostat + PlaceboAstraZenecaPhase 3
77
TralokinumabAstraZenecaPhase 3
77
Baxdrostat + PlaceboAstraZenecaPhase 3
77
BenralizumabAstraZenecaPhase 3
77
Baxdrostat + PlaceboAstraZenecaPhase 2
52
Experimental: TralokinumabAstraZenecaPhase 3
77
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
CIN-107 + PlaceboAstraZenecaPhase 2
52
Pegloticase + Methotrexate (MTX)AmgenApproved
84
Pegloticase + MethotrexateAmgenPhase 3
76
Pegloticase + Methotrexate (MTX)AmgenApproved
84
Pegloticase with MTXAmgenApproved
84
abrocitinibPfizerPre-clinical
22
REGN5381 + PlaceboRegeneron PharmaceuticalsPhase 2
51
SAL0140 + SAL0140 placeboShenzhen Salubris PharmaceuticalsPhase 1
32

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84